Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
NCT06411002
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
27
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Frown Lines
Interventions
DRUG:
DAXXIFY
Sponsor
Revance Therapeutics, Inc.